Vertex Pharmaceuticals' (VRTX) triple combination medicine deutivacaftor, tezacaftor,vanzacaftor was approved by the UK's Medicines and Healthcare products Regulatory Agency for treating cystic fibrosis in patients aged six and older with responsive CFTR mutations, including F508del, the agency said in a statement on Friday.
The treatment is marketed under the brand name of Alyftrek.
Two randomized phase 3 studies involving 480 participants aged 12 years and older, Alyftrek was found to be as effective at improving lung function as ivacaftor/tezacaftor/elexacaftor or Kaftrio, and more effective at reducing sweat chloride levels compared to placebo.
The agency said grapefruit-containing food or drink should be avoided during treatment.
The drug's common side effects include headache and diarrhoea.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。